M&A / Deals UPDATE: Kailera breaks biotech IPO record with $625M debut BioSpaceObesity-focused Kailera Therapeutics debuted on the Nasdaq Friday after raising a record $625 million, beating Moderna's $600 million from 2018.M&A / DealsRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) BioSpace Obesity-focused Kailera Therapeutics debuted on the Nasdaq Friday after raising a record $625 million, beating Moderna’s $600 million from 2018. M&A / DealsRead full story Post navigation Previous: RFK Jr. defends Makary, claims pharma ‘owns’ Congress and mediaNext: S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
